Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation

Smagur, Andrzej; Mitrus, Iwona; Ciomber, Agnieszka; Panczyniak, Katarzyna; Fidyk, Wojciech; Saduś-Wojciechowska, Maria; Hołowiecki, Jerzy; Giebel, Sebastian

doi:10.1111/vox.12238

Cited by 13 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Xeno-contamination reactions are rare and commonly associated with the presence of supportive xenogenic components in cell products. Commonly cryopreservation (50,51) and expanding media containing fetal bovine serum (FBS), human serum albumin, or patient's autologous plasma (52)(53)(54). Today, FBS is excluded from the majority of clinical protocols due to the risk of disease transmission and xenogeneic immune reactions and replaced by alternative protein sources (55,56).…”

Section: Xeno-contamination Reactions Caused By Components Of Culture...mentioning

confidence: 99%

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies

Baranovskii¹,

Klabukov²,

Arguchinskaya³

et al. 2022

Stem Cell Investig

View full text Add to dashboard Cite

Numerous clinical studies have shown a wide clinical potential of mesenchymal stromal cells (MSCs) application. However, recent experience has accumulated numerous reports of adverse events and side effects associated with MSCs therapy. Furthermore, the strategies and methods of MSCs therapy did not change significantly in recent decades despite the clinical impact and awareness of potential complications.An extended understanding of limitations could lead to a wider clinical implementation of safe cell therapies and avoid harmful approaches. Therefore, our objective was to summarize the possible negative effects observed during MSCs-based therapies. We were also aimed to discuss the risks caused by weaknesses in cell processing, including isolation, culturing, and storage. Cell processing and cell culture could dramatically influence cell population profile, change protein expression and cell differentiation paving the way for future negative effects. Long-term cell culture led to accumulation of chromosomal abnormalities.Overdosed antibiotics in culture media enhanced the risk of mycoplasma contamination. Clinical trials reported thromboembolism and fibrosis as the most common adverse events of MSCs therapy. Their delayed manifestation generally depends on the patient's individual phenotype and requires specific awareness during the clinical trials with obligatory inclusion in the patient' informed consents. Finally we prepared the safety checklist, recommended for clinical specialists before administration or planning of MSCs therapy.

show abstract

Section: Xeno-contamination Reactions Caused By Components Of Culture...mentioning

confidence: 99%

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies

Baranovskii¹,

Klabukov²,

Arguchinskaya³

et al. 2022

Stem Cell Investig

View full text Add to dashboard Cite

show abstract

“…Cryopreservation 315,316 and expanding media that contain human serum albumin, the patient's plasma, or fetal bovine serum are the most common causes of contamination. 317,318 There is a large amount of variation in culture-expanded MSCs concerning the shape of cells, physiological functions, and activities; this variation is a key contributor to MSC heterogeneity. 319 As a consequence of this, cell-derived compounds and experimental models that can be duplicated under the same conditions may have affinities that are difficult to anticipate.…”

Section: Obstacles and Challenges With Mscs Transplantation Therapymentioning

confidence: 99%

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Hetta,

Elsaghir,

Sijercic

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundDiabetes has evolved into a worldwide public health issue. One of the most serious complications of diabetes is diabetic foot ulcer (DFU), which frequently creates a significant financial strain on patients and lowers their quality of life. Up until now, there has been no curative therapy for DFU, only symptomatic relief or an interruption in the disease's progression. Recent studies have focused attention on mesenchymal stem cells (MSCs), which provide innovative and potential treatment candidates for several illnesses as they can differentiate into various cell types. They are mostly extracted from the placenta, adipose tissue, umbilical cord (UC), and bone marrow (BM). Regardless of their origin, they show comparable features and small deviations. Our goal is to investigate MSCs' therapeutic effects, application obstacles, and patient benefit strategies for DFU therapy.MethodologyA comprehensive search was conducted using specific keywords relating to DFU, MSCs, and connected topics in the databases of Medline, Scopus, Web of Science, and PubMed. The main focus of the selection criteria was on English‐language literature that explored the relationship between DFU, MSCs, and related factors.Results and DiscussionNumerous studies are being conducted and have demonstrated that MSCs can induce re‐epithelialization and angiogenesis, decrease inflammation, contribute to immunological modulation, and subsequently promote DFU healing, making them a promising approach to treating DFU. This review article provides a general snapshot of DFU (including clinical presentation, risk factors and etiopathogenesis, and conventional treatment) and discusses the clinical progress of MSCs in the management of DFU, taking into consideration the side effects and challenges during the application of MSCs and how to overcome these challenges to achieve maximum benefits.ConclusionThe incorporation of MSCs in the management of DFU highlights their potential as a feasible therapeutic strategy. Establishing a comprehensive understanding of the complex relationship between DFU pathophysiology, MSC therapies, and related obstacles is essential for optimizing therapy outcomes and maximizing patient benefits.

show abstract

“…Another adverse event is that the medium is contaminated with xenomorphs, typically due to ultracryopreservation 43,44 . In addition, media containing fetal bovine serum (FBS), human serum albumin, or the patient's own plasma are prone to various contaminations 45,46 . At present, FBS has not been allowed for clinical use because of the risk of heteroimmune response and disease transmission, and has been replaced by alternative protein sources 47 .…”

Section: Stromal Cell‐based Treatment For Diabetic Wound Healingmentioning

confidence: 99%

“…43,44 In addition, media containing fetal bovine serum (FBS), human serum albumin, or the patient's own plasma are prone to various contaminations. 45,46 At present, FBS has not been allowed for clinical use because of the risk of heteroimmune response and disease transmission, and has been replaced by alternative protein sources. 47 But in laboratory studies, FBS is still used to culture cells.…”

Section: Stromal Cell-based Treatment For Diabetic Wound Healingmentioning

confidence: 99%

Advances in mesenchymal stromal cells and nanomaterials for diabetic wound healing

Hou

Zhang

2023

Diabetes Metabolism Res

View full text Add to dashboard Cite

The delayed healing of diabetic wounds (DBW) will not only afflict patients, but also lead to amputation and even death in serious cases, which will create many negative effects on society and the country. Mesenchymal stromal cells (MSCs) have attracted extensive attention for their applications in chronic wound healing due to their excellent cytokine secretion ability and regulation of inflammation. Mesenchymal stromal cells can be used alone or wrapped with carrier/matrix and applied to enhance healing in the wound area. In this review, the etiology of the slow healing of DBW and the mechanism by which MSCs promote the healing of DBW were explored. In addition, we summarised the current research progress on the use of stromal cell-loaded biomaterials for wound healing in diabetic animal models. At the end of the article, we pointed out the challenges and improvement strategies for stromal cell therapy applied to DBW in future clinical practice. K E Y W O R D Sbiomaterials, diabetic foot ulcers, mesenchymal stromal cells, wound healing | INTRODUCTIONDiabetes mellitus is a group of metabolic diseases caused by a complex interplay of genetic, immune, and environmental factors. These diseases are characterised by chronic hyperglycaemia, which is caused by impaired insulin secretion or impaired insulin action, or both. 1 The long-term presence of hyperglycaemia can lead to chronic damage and dysfunction of various tissues. Diabetes can be divided into four types, namely type 1 diabetes, type 2 diabetes, other specific diabetes types, and gestational diabetes. 1 Type 1 diabetes is caused by the autoimmune system destroying the insulin-producing beta cells 1-4 ; type 2 diabetes is caused by insulin resistance in tissue cells, which allows less glucose to enter the cells and participate in the production of calories, while it allows more glucose to remain in the blood. 1,5 Gestational diabetes, on the other hand, is similar to type 2 diabetes in that it also stems from cellular insulin resistance, although its insulin resistance is due to hormones secreted by women during pregnancy. 1,6 Other specific diabetes is diabetes induced by specific etiologies, such as mumps, chronic pancreatitis, etc. or long-term steroid use. 1,6 In addition to hyperglycaemia, the clinical manifestations of diabetic patients are the typical "three more and one less", that is, drinking more, urinating more, eating more, and weight loss.

show abstract

Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation

Abstract: HSA in cryoprotective mixture may be replaced by AP without negative impact on cell recovery, clonogenic potential or engraftment.

Cited by 13 publications

References 41 publications

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies

Adverse events, side effects and complications in mesenchymal stromal cell-based therapies

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Advances in mesenchymal stromal cells and nanomaterials for diabetic wound healing

Contact Info

Product

Resources

About